Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Team

Editorial Team

International

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.

Clinical Trials Deals

BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.

Clinical Trials Deals

BIO Notebook Day 3: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.

Business Strategies Deals

Pharma vs The IRA — Industry Leaders React To Merck Lawsuit

Execs offer a guarded reaction, noting the need for continued dialogue, but emphasize the dire threat that the pricing program poses to the pharma business model.

Pricing Debate Legal Issues

BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes

Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’

M & A Leadership
See All
UsernamePublicRestriction

Register